Adjuvant Combinations of NKT Activator, CD40 Agent, CD40 Agonist, and Optional Antigen, the Use Through Inducing Synergistic Cellular Immunity

摘要

Adjuvant combinations comprising at least one NKT activator, such as alpha-galactosylceramide (α-Gal-Cer) or iGb3, a CD40 agonist and optionally an antigen are disclosed. The use of these immune adjuvants for treatment of various chronic diseases such as cancers is also provided.